| GeneLibs

题目:: Screening for prostate cancer.
作者:: Postma(R),Schröder(F H)
状态:: 发布时间2005-04-05 , 更新时间 2006-11-15
期刊:: Eur J Cancer
摘要:: Epidemiologically, prostate cancer is the most common cancer in the Western world after skin cancer. To date, it is still unknown whether screening for prostate cancer is justified, because results of randomised clinical trials are not yet available. The available screening tests (i.e. prostate-specific antigen (PSA) test) do not always detect cancers that otherwise would have resulted in prostate cancer mortality. Favourable results from prostate cancer screening include an increasing number of men with localised disease and an increase in the number of well-differentiated tumours. However, the risk of overdiagnosis and subsequent over-treatment (due to the diagnosis of localised disease), using aggressive therapies fuels arguments against screening. Therefore, until more evidence is available proving otherwise, prostate cancer screening can only be justified in the context of clinical trials.
语言:: eng
DOI:: 10.1016/j.ejca.2004.12.029

文献库文献相关信息